Regulus Therapeutics (NASDAQ:RGLS) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.46 and traded as high as $1.84. Regulus Therapeutics shares last traded at $1.78, with a volume of 833,887 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have commented on RGLS shares. Canaccord Genuity Group reissued a "buy" rating and set a $28.00 target price on shares of Regulus Therapeutics in a research note on Monday, March 17th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Wells Fargo & Company raised shares of Regulus Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $3.00 to $6.00 in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Regulus Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $12.75.

Regulus Therapeutics Stock Down 0.3 %

The company's 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.46. The firm has a market cap of $128.84 million, a PE ratio of -1.82 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.20). During the same period in the previous year, the company posted ($0.40) EPS. On average, analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Remove Ads

Insiders Place Their Bets

In other news, CEO Joseph P. Hagan acquired 50,000 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the transaction, the chief executive officer now directly owns 260,808 shares in the company, valued at approximately $284,280.72. This represents a 23.72 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 4.35% of the stock is owned by company insiders.

Institutional Trading of Regulus Therapeutics

A number of large investors have recently made changes to their positions in RGLS. Velan Capital Investment Management LP acquired a new stake in shares of Regulus Therapeutics in the fourth quarter valued at about $111,000. Octagon Capital Advisors LP increased its holdings in shares of Regulus Therapeutics by 13.7% in the 4th quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock worth $7,661,000 after acquiring an additional 585,101 shares during the period. Millennium Management LLC boosted its position in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock worth $3,464,000 after buying an additional 900,743 shares during the period. PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter worth $95,000. Finally, Barclays PLC increased its stake in Regulus Therapeutics by 13.9% during the 4th quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 11,770 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.